Jaguar Health Inc (NASDAQ:JAGX) shares saw unusually-high trading volume on Friday . Approximately 4,086,300 shares were traded during trading, an increase of 233% from the previous session’s volume of 1,225,953 shares.The stock last traded at $0.88 and had previously closed at $0.81.
JAGX has been the subject of several research reports. Zacks Investment Research upgraded Jaguar Health from a “sell” rating to a “hold” rating in a report on Thursday. HC Wainwright reiterated a “buy” rating and set a $3.00 price target (down from $10.00) on shares of Jaguar Health in a report on Monday, November 18th. Finally, ValuEngine upgraded Jaguar Health from a “hold” rating to a “buy” rating in a report on Thursday, November 14th.
The firm has a market capitalization of $41.29 million, a price-to-earnings ratio of -0.01 and a beta of 0.80. The company has a current ratio of 0.88, a quick ratio of 0.61 and a debt-to-equity ratio of 0.61. The company has a fifty day moving average price of $0.67 and a 200-day moving average price of $1.27.
Jaguar Health (NASDAQ:JAGX) last announced its quarterly earnings results on Thursday, November 14th. The biotechnology company reported ($1.94) earnings per share (EPS) for the quarter, missing the Thomson Reuters’ consensus estimate of ($0.25) by ($1.69). The firm had revenue of $0.97 million for the quarter, compared to analyst estimates of $4.22 million. Jaguar Health had a negative net margin of 771.25% and a negative return on equity of 675.03%. As a group, sell-side analysts predict that Jaguar Health Inc will post 4.34 EPS for the current fiscal year.
A hedge fund recently bought a new stake in Jaguar Health stock. Wedbush Securities Inc. purchased a new stake in shares of Jaguar Health Inc (NASDAQ:JAGX) in the 3rd quarter, according to its most recent filing with the Securities and Exchange Commission. The fund purchased 25,100 shares of the biotechnology company’s stock, valued at approximately $33,000. Wedbush Securities Inc. owned about 0.05% of Jaguar Health at the end of the most recent reporting period. Hedge funds and other institutional investors own 0.16% of the company’s stock.
About Jaguar Health (NASDAQ:JAGX)
Jaguar Health, Inc, a commercial stage natural-products pharmaceuticals company, focuses on developing gastrointestinal products for human prescription use and animals worldwide. The company, through its wholly-owned subsidiary, Napo Pharmaceuticals, Inc, focuses on developing and commercializing proprietary human gastrointestinal pharmaceuticals for the global marketplace from plants used traditionally in rainforest areas.
Further Reading: What is a stock buyback?
Receive News & Ratings for Jaguar Health Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Jaguar Health and related companies with MarketBeat.com's FREE daily email newsletter.